News

Behind every triumphant headline announcing a new breakthrough medicine, there’s an often untold story of years or even decades of basic research in the lab, and mad scrambles for funding to perform animal model studies and early stage human clinical trials that attract industry investment to move into larger trials. Layer onto that burden the […]

Several Canadian-made cell therapies will take a major step closer to the clinic thanks to a new collaboration between the Ontario Institute for Regenerative Medicine (OIRM) and the Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine (C3i).

The Center for Commercialization of Cancer Immunotherapy (C3i) and the Centre intégré universitaire de santé et de services sociaux de l’Est-de-l’Île-de-Montréal (CIUSSS-EMTL) are proud to announce the participation of Gilead Sciences Canada, Inc. in supporting the development of a Lymphoma Registry.

Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple cancers, today announced a strategic relationship with the Centre for Commercialisation of Cancer Immunotherapy (C3i), a catalyst for accelerating market access of breakthrough innovations to fight cancer. Under the terms of the agreement, C3i will deliver cell therapy products for Triumvira’s global Phase 1 and 2 clinical trials and has committed to underwrite an investment in the company.

The Center for Commercialization of Cancer Immunotherapy (C3i) is proud to announce a partnership with Hôpital Maisonneuve-Rosemont (HMR) and Dr. Isabelle Fleury, Hematologist and Medical Oncologist at HMR, to support the development of a Lymphoma Registry.

C3i will attend both the Cell and Gene Therapy World and Immuno-Oncology Frontiers World (part of the World Stem Cell Summit 2018) in Miami to engage with researchers, clinicians and industry leaders in the Stem Cell field.

C3i will attend the 10th Canadian Cancer Immunotherapy Consortium in Montreal from December 13th to 15th to engage with researchers, clinicians and industry leaders in the Cancer Immunotherapy field.

C3i will attend the 59th ASH Annual Meeting and Exposition in Atlanta from December 9th to 12th to engage with researchers, clinicians and industry leaders in the Hematology field. François Bettez, our CEO as well as Dr Lambert Busque our CMO, and Dr Denis-Claude Roy ou CSO, will be representing and promoting C3i for its outstanding capacity to help biotech companies and pharmas to achieve their objectives. 

C3i will attend the Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam from December 5th to 7th to engage with researchers, clinicians and industry leaders in the cGMP manufacturing area. Arnaud will be representing and promoting C3i for its cGMP manufacturing commercial capacity, adapted to the needs of our numerous partners.  Get in touch to know […]